AVISA Study – COVID-19
since 2021
The AVISA Study, designed to investigate the transmission of SARS-CoV-2 infection, the duration of immunity after infection, and the medium-term consequences of the disease in different population groups, aimed to support the production of evidence-based knowledge about the coronavirus to inform the development of vaccination strategies for the population.
An initiative of the Butantan Institute and the Butantan Foundation, with support from Umane and the Todos Pela Saúde Institute, the study recruited 3,077 participants who were followed for a period of 60 weeks between 2021 and 2022. Monitoring included monthly rapid tests for COVID-19 detection and quarterly blood collection to assess immunity against the virus. In 2024, all stages of analysis and results coding were completed.
The findings were presented at academic events throughout the year, including the 42nd Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID 2024) in Copenhagen, Denmark, as well as Brazilian congresses on Tropical Medicine and Epidemiology. The presentations covered the epidemiological scenarios of the pandemic in Brazil, patterns of incidence and prevalence over time in the cohort, the relationship between sociodemographic and behavioral characteristics and SARS-CoV-2 infection, and the application of statistical models to associate factors with infection rates.
Support for the production of evidence-based knowledge on the coronavirus to inform the development of vaccination strategies for the population.
research participants
research centers involved in the study, from four regions of Brazil
presentations at academic conferences in 2024: 4 in Brazil and 1 in Denmark
scientific articles in preparation